Correlation Between Inhibrx and Catalyst Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Inhibrx and Catalyst Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and Catalyst Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inhibrx and Catalyst Pharmaceuticals, you can compare the effects of market volatilities on Inhibrx and Catalyst Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of Catalyst Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and Catalyst Pharmaceuticals.

Diversification Opportunities for Inhibrx and Catalyst Pharmaceuticals

-0.18

Correlation Coefficient

Inhibrx  Catalyst Pharmaceuticals

Good diversification

The 3 months correlation between Inhibrx and Catalyst is -0.18. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and Catalyst Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Catalyst Pharmaceuticals and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with Catalyst Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Catalyst Pharmaceuticals has no effect on the direction of Inhibrx i.e., Inhibrx and Catalyst Pharmaceuticals go up and down completely randomly.

Pair Corralation between Inhibrx and Catalyst Pharmaceuticals

Given the investment horizon of 90 days Inhibrx is expected to under-perform the Catalyst Pharmaceuticals. In addition to that, Inhibrx is 1.04 times more volatile than Catalyst Pharmaceuticals. It trades about -0.02 of its total potential returns per unit of risk. Catalyst Pharmaceuticals is currently generating about 0.09 per unit of volatility. If you would invest  2,107  in Catalyst Pharmaceuticals on December 30, 2024 and sell it today you would earn a total of  362.00  from holding Catalyst Pharmaceuticals or generate 17.18% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Inhibrx  vs.  Catalyst Pharmaceuticals

Inhibrx

Risk-Adjusted Performance

Very Weak

Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Inhibrx is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Catalyst Pharmaceuticals

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Catalyst Pharmaceuticals are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Catalyst Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Inhibrx and Catalyst Pharmaceuticals

The main advantage of trading using opposite Inhibrx and Catalyst Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, Catalyst Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Pharmaceuticals will offset losses from the drop in Catalyst Pharmaceuticals' long position.

The idea behind Inhibrx and Catalyst Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.